General Pharmacology Practice Questions

Q: Which of the following facts is false regarding halothane?

It has no effect on vagal tone. **Explanation:** Halothane is a potent volatile anesthetic agent. The statement that it has no effect on vagal tone is **false** because halothane actually **increases vagal tone**, which frequently leads to **bradycardia**. This vagomimetic effect is a characteristic feature of halothane and can be countered by pre-medication with atropine. **Analysis of Options:** * **Option A (Correct Fact):** Halothane is a non-flammable, non-irritating, and **pleasant-smelling** liquid. Its non-pungent nature makes it an excellent choice for smooth inhalation induction, especially in pediatric patients. * **Option C (Correct Fact):** Halothane **sensitizes the myocardium to catecholamines** (epinephrine/norepinephrine). This significantly increases the risk of ventricular arrhythmias, especially if exogenous adrenaline is administered during surgery. * **Option D (Correct Fact):** Halothane undergoes significant hepatic metabolism (up to 20%). A reactive metabolite (trifluoroacetylated protein) can trigger an immune-mediated reaction leading to **Halothane Hepatitis**, typically occurring postoperatively. **High-Yield NEET-PG Pearls:** 1. **Malignant Hyperthermia:** Halothane is a known trigger (Treatment: Dantrolene). 2. **Uterine Effect:** It causes significant uterine relaxation, which can lead to postpartum hemorrhage (PPH); hence, it is avoided during labor. 3. **Blood-Gas Partition Coefficient:** It has a relatively high coefficient (~2.3), leading to slower induction and recovery compared to Sevoflurane or Desflurane. 4. **Cerebral Effect:** It is a potent cerebral vasodilator, which can increase intracranial pressure (ICP).

Q: Therapeutic Drug Monitoring (TDM) is indicated for which of the following drugs?

Metformin. **Explanation** **Therapeutic Drug Monitoring (TDM)** is a clinical practice where the plasma concentration of a drug is measured to maintain it within a specific "therapeutic window." It is typically indicated for drugs with a narrow therapeutic index, high inter-individual pharmacokinetic variability, or a direct correlation between plasma levels and toxicity [1]. **Why Metformin is the Correct Answer (in the context of NOT requiring TDM):** Metformin is an oral hypoglycemic agent used for Type 2 Diabetes. It has a **wide therapeutic index**, and its efficacy is monitored clinically by measuring blood glucose levels and HbA1c, rather than plasma drug concentrations [4]. Therefore, TDM is **not** indicated for Metformin. **Analysis of Incorrect Options (Drugs requiring TDM):** * **Theophylline:** A bronchodilator with a narrow therapeutic window [1]. Toxicity (arrhythmias, seizures) can occur at levels only slightly higher than therapeutic doses. * **Lithium:** Used in Bipolar Disorder; it has an extremely narrow therapeutic range (0.6–1.2 mEq/L). Levels >1.5 mEq/L are toxic, necessitating frequent monitoring. * **Phenytoin:** An antiepileptic that exhibits **zero-order (saturation) kinetics** at therapeutic doses [2]. Small dose increases can lead to disproportionately large increases in plasma levels and toxicity (ataxia, nystagmus) [3]. **High-Yield Clinical Pearls for NEET-PG:** * **Indications for TDM:** Narrow therapeutic index (Digoxin, Aminoglycosides), non-linear kinetics (Phenytoin), or drugs where toxicity is difficult to distinguish from the disease (Theophylline) [1], [2]. * **TDM is NOT required for:** Drugs with easily measurable physiological markers (e.g., BP for Antihypertensives, INR for Warfarin, Blood sugar for Metformin/Insulin) [4]. * **Sampling Time:** TDM is usually performed at **steady state** (after 4–5 half-lives) using "trough" concentrations (just before the next dose) [1].

Q: Phocomelia is an adverse effect due to which of the following teratogens?

Thalidomide. **Explanation:** **Thalidomide (Correct Answer):** Phocomelia is a classic teratogenic manifestation characterized by "seal-like limbs," where the long bones of the limbs are absent or significantly shortened, and the hands/feet are attached directly to the trunk. Thalidomide, originally used as a sedative and anti-emetic for morning sickness in the 1950s, was found to inhibit angiogenesis (via inhibition of bFGF and VEGF) and cause oxidative stress during the critical period of limb development (days 24–36 of gestation). **Analysis of Incorrect Options:** * **Warfarin:** Causes **Fetal Warfarin Syndrome**, characterized by nasal hypoplasia, stippled epiphyses (chondrodysplasia punctata), and CNS defects. It does not cause phocomelia. * **Enalapril (ACE Inhibitors):** These are associated with **fetal renal dysgenesis**, oligohydramnios, and skull ossification defects. They are contraindicated especially in the 2nd and 3rd trimesters. * **Phenytoin:** Causes **Fetal Hydantoin Syndrome**, which presents with craniofacial abnormalities (cleft lip/palate), microcephaly, and hypoplastic phalanges/nails. **High-Yield Clinical Pearls for NEET-PG:** * **Thalidomide's current use:** Despite its history, it is now used for Erythema Nodosum Leprosum (ENL) and Multiple Myeloma due to its immunomodulatory and anti-angiogenic properties. * **Critical Period:** Teratogens typically have the most profound effect during **organogenesis** (weeks 3 to 8 of gestation). * **Other limb defects:** Sodium Valproate is specifically linked to neural tube defects, while Lithium is linked to **Ebstein’s anomaly** (tricuspid valve defect).

Q: A newborn developed cleft lip, cleft palate, and atrial septal defect. Which of the following drugs, if consumed by the mother during pregnancy, is most likely to cause these congenital anomalies?

Isotretinoin. **Explanation:** The correct answer is **Isotretinoin (Option D)**. Isotretinoin, a vitamin A derivative used for severe acne, is one of the most potent human teratogens. It interferes with neural crest cell migration and HOX gene expression during embryogenesis. Exposure during the first trimester leads to **"Retinoic Acid Embryopathy,"** characterized by craniofacial abnormalities (cleft lip/palate, microtia), CNS defects, and cardiovascular malformations like Atrial Septal Defect (ASD) or Tetralogy of Fallot. **Analysis of Incorrect Options:** * **Digoxin (A):** It is generally considered safe during pregnancy and is often the drug of choice for treating fetal supraventricular tachycardia. It is not associated with structural malformations. * **Methanol (B):** While toxic to the mother (causing metabolic acidosis and blindness), it is not a classic teratogen associated with this specific triad of structural defects. Ethanol, however, causes Fetal Alcohol Syndrome (maxillary hypoplasia, smooth philtrum). * **ACE Inhibitors (C):** These are contraindicated in the 2nd and 3rd trimesters. They cause **"ACEI Fetopathy,"** characterized by renal dysgenesis, oligohydramnios, and skull hypoplasia, rather than first-trimester structural clefts. **NEET-PG High-Yield Pearls:** * **Isotretinoin Rule:** Female patients must follow the **iPLEDGE program**: two forms of contraception and two negative pregnancy tests before starting therapy. * **Critical Period:** The heart and face develop between weeks 3–8; this is the period of maximum teratogenic risk. * **Other Retinoid Facts:** Etretinate has a very long half-life (120 days); pregnancy should be avoided for 3 years after discontinuation.

Q: Zero-order kinetics occur in which of the following drugs at high doses?

Phenytoin and Theophylline. ### Explanation **1. Understanding Zero-Order Kinetics** Most drugs follow **First-Order Kinetics**, where a constant *fraction* of the drug is eliminated per unit of time (rate is proportional to plasma concentration). However, some drugs follow **Zero-Order Kinetics** (Non-linear kinetics), where a constant *amount* of the drug is eliminated per unit of time, regardless of concentration. This occurs because the metabolic enzymes or transport systems become **saturated**. **Phenytoin** and **Theophylline** are classic examples of drugs that exhibit "Michaelis-Menten kinetics." At low therapeutic doses, they follow first-order kinetics, but as doses increase and metabolic pathways saturate, they shift to zero-order kinetics. This shift is clinically dangerous because a small increase in dose can lead to a disproportionately large increase in plasma concentration and toxicity. **2. Analysis of Incorrect Options** * **Option B:** **Digoxin** and **Propranolol** follow first-order kinetics. Propranolol has high first-pass metabolism, but its elimination rate remains proportional to its concentration. * **Option C:** **Amiloride** (diuretic) and **Probenecid** (uricosuric) follow first-order kinetics. * **Option D:** While **Theophylline** is correct, **Lithium** follows first-order kinetics and is primarily excreted unchanged by the kidneys. **3. NEET-PG High-Yield Pearls** To remember drugs following Zero-Order Kinetics, use the mnemonic **"ZERO WATTS"**: * **W:** Warfarin (at very high doses) * **A:** Alcohol (Ethanol) - *The most common example* * **T:** Theophylline / Tolbutamide * **T:** T-Salicylates (Aspirin) * **S:** Specific drugs like Phenytoin **Key Concept:** In zero-order kinetics, the **half-life ($t_{1/2}$) is not constant**; it increases as the plasma concentration increases. This makes therapeutic drug monitoring (TDM) essential for Phenytoin and Theophylline.

Q: Ranibizumab is a monoclonal antibody against which of the following targets?

VEGF. **Explanation:** **Ranibizumab** is a recombinant humanized monoclonal antibody fragment (Fab) designed to bind and inhibit **Vascular Endothelial Growth Factor A (VEGF-A)**. VEGF is a potent cytokine that promotes angiogenesis (new blood vessel formation) and increases vascular permeability. In ophthalmology, excessive VEGF levels lead to pathological neovascularization and macular edema. By neutralizing VEGF, Ranibizumab prevents the growth of abnormal vessels and reduces leakage, making it a cornerstone in treating **Wet Age-related Macular Degeneration (AMD)**, Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO). **Analysis of Incorrect Options:** * **A. IL-6:** Interleukin-6 is a pro-inflammatory cytokine. Inhibitors like **Tocilizumab** are used in Rheumatoid Arthritis and Giant Cell Arteritis, but not as primary anti-angiogenic agents in the eye. * **B. CD-20:** This is a surface antigen on B-cells. **Rituximab** is the monoclonal antibody targeting CD-20, used in lymphomas and certain autoimmune conditions (e.g., Ocular Cicatricial Pemphigoid). * **D. EGFR:** Epidermal Growth Factor Receptor inhibitors like **Cetuximab** are used in treating systemic malignancies (e.g., colorectal cancer), not retinal vascular diseases. **High-Yield Clinical Pearls for NEET-PG:** * **Ranibizumab vs. Bevacizumab:** Ranibizumab is a Fab fragment (smaller molecule), whereas Bevacizumab is a full-length antibody. * **Aflibercept:** Another common agent, acts as a "VEGF Trap" by binding to VEGF-A, VEGF-B, and Placental Growth Factor (PlGF). * **Route of Administration:** These drugs are administered via **intravitreal injection** to ensure high local concentration and minimal systemic side effects. * **Common Indication:** The most frequent "high-yield" indication tested is **Exudative (Wet) AMD**.

Q: Which of the following monoclonal antibodies is a humanized antibody?

Palivizumab. The nomenclature of monoclonal antibodies (mAbs) is a high-yield topic for NEET-PG. The origin of an antibody is determined by the **source substem** (the letters immediately preceding the suffix "-mab"). ### **1. Why Palivizumab is Correct** The substem **"-zu-"** indicates a **Humanized** antibody. These are approximately 95% human and 5% murine (mouse). The CDR (complementarity-determining regions) are derived from mice, while the rest of the immunoglobulin molecule is human. * **Palivizumab:** Used for the prevention of Respiratory Syncytial Virus (RSV) infections in high-risk infants. ### **2. Analysis of Incorrect Options** * **Rituximab (Option A):** Contains the substem **"-xi-"**, which stands for **Chimeric** antibody (~65% human). It targets CD20 and is used in Non-Hodgkin Lymphoma and Rheumatoid Arthritis. * **Infliximab (Option C):** Also a **Chimeric** antibody (**"-xi-"**). It is a TNF-alpha inhibitor used in Crohn’s disease and Ulcerative Colitis. * **Basiliximab (Option D):** A **Chimeric** antibody (**"-xi-"**). It is an IL-2 receptor antagonist used to prevent acute organ transplant rejection. ### **3. High-Yield Clinical Pearls for NEET-PG** To quickly identify the source of any mAb, remember these substems: * **-omab:** 100% Mouse (Murine) – e.g., Muromonab. * **-ximab:** Chimeric (Mixed) – e.g., Rituximab, Cetuximab. * **-zumab:** Humani**z**ed – e.g., Trastu**z**umab, Beva**z**izumab. * **-umab:** 100% H**u**man – e.g., Adalim**u**mab, Panitum**u**mab. **Note:** Humanized and Human antibodies have lower immunogenicity and a lower risk of infusion reactions compared to chimeric or murine antibodies.

Q: What is the primary objective of Phase II in a clinical drug trial?

Therapeutic exploration and dose ranging. ### Explanation **Phase II** of a clinical trial is primarily focused on **Therapeutic Exploration**. After Phase I confirms safety in healthy volunteers, Phase II involves a small group of patients (100–300) suffering from the target disease. The primary objectives are to evaluate **efficacy**, establish the **dose-response relationship**, and determine the optimal dose range for larger trials. #### Analysis of Options: * **Option B (Correct):** Phase II aims to see if the drug actually works in patients (efficacy) and identifies the minimum effective dose and maximum tolerated dose (**dose-ranging**). * **Option A (Incorrect):** This describes **Phase I**. Phase I focuses on human pharmacology, safety, and pharmacokinetics, typically conducted in healthy volunteers (except for toxic drugs like anti-cancer agents). * **Option C (Incorrect):** This describes **Phase III (Therapeutic Confirmation)**. Phase III involves large-scale multicentric trials to compare the new drug against existing "gold standard" treatments or placebos to confirm clinical benefit. * **Option D (Incorrect):** This describes **Phase IV (Post-marketing Surveillance)**. It occurs after the drug is marketed to detect rare long-term adverse effects and monitor performance in the general population. #### High-Yield NEET-PG Pearls: * **Phase 0:** Also called **Microdosing** studies; uses sub-therapeutic doses to study pharmacokinetics (PK) without pharmacological effects. * **Phase I:** First stage in humans; focuses on **Safety** and **Tolerability**. * **Phase II:** Divided into **IIa** (pilot study for efficacy) and **IIb** (pivotal study for dose-finding). This phase has the highest failure rate in drug development. * **Phase III:** Required for **Marketing Authorization** (NDA filing). * **Phase IV:** Identifies **Rare Adverse Events** (e.g., Phocomelia, Rofecoxib-induced cardiotoxicity).

Q: Which category of drugs is difficult to market and highly expensive to produce?

Orphan drugs. **Explanation:** **Orphan drugs** are the correct answer because they are intended for the treatment, prevention, or diagnosis of **rare diseases** (e.g., Gaucher’s disease, Cystic Fibrosis, or Leprosy). Because the patient population is so small, pharmaceutical companies find it commercially unviable to develop these drugs due to the high cost of R&D versus the limited potential for profit. To encourage their production, governments provide incentives like tax credits and extended patent exclusivity. **Analysis of Incorrect Options:** * **B. Rare drugs:** This is a distractor term. While orphan drugs treat rare diseases, "rare drugs" is not a formal pharmacological classification used in drug regulation. * **C. Over the counter (OTC) drugs:** These are drugs that can be sold without a prescription (e.g., Paracetamol). They are generally inexpensive to produce, have a massive market, and are highly profitable. * **D. Emergency drugs:** These are life-saving medications required for immediate use (e.g., Adrenaline, Atropine). They have a stable market demand and are standard stock in all healthcare facilities. **High-Yield Clinical Pearls for NEET-PG:** * **Definition:** In the US, an orphan disease is defined as one affecting fewer than **200,000 people**. * **Examples of Orphan Drugs:** **Digoxin immune Fab** (for digitalis toxicity), **Fomepizole** (for methanol poisoning), **Amphotericin B** (for Kala-azar in specific regions), and **Thalidomide** (for Lepra reaction). * **Regulatory Act:** The **Orphan Drug Act (1983)** was the first major legislation to provide incentives for the development of these agents.

Question 1

Which of the following facts is false regarding halothane?

Accepted Answer

It has no effect on vagal tone

Answer

It is a pleasant smelling gas

Answer

It sensitizes the myocardium to catecholamines

Answer

It can cause postoperative hepatitis

Question 2

Therapeutic Drug Monitoring (TDM) is indicated for which of the following drugs?

Accepted Answer

Metformin

Answer

Theophylline

Answer

Lithium

Answer

Phenytoin

Question 3

Phocomelia is an adverse effect due to which of the following teratogens?

Accepted Answer

Thalidomide

Answer

Warfarin

Answer

Enalapril

Answer

Phenytoin

Question 4

A newborn developed cleft lip, cleft palate, and atrial septal defect. Which of the following drugs, if consumed by the mother during pregnancy, is most likely to cause these congenital anomalies?

Accepted Answer

Isotretinoin

Answer

Digoxin

Answer

Methanol

Answer

ACE Inhibitors

Question 5

Zero-order kinetics occur in which of the following drugs at high doses?

Accepted Answer

Phenytoin and Theophylline

Answer

Digoxin and Propranolol

Answer

Amiloride and Probenecid

Answer

Lithium and Theophylline

Question 6

Ranibizumab is a monoclonal antibody against which of the following targets?

Accepted Answer

VEGF

Answer

IL-6

Answer

CD-20

Answer

EGFR

Question 7

Which of the following monoclonal antibodies is a humanized antibody?

Accepted Answer

Palivizumab

Answer

Rituximab

Answer

Infliximab

Answer

Basilximab

Question 8

What is the primary objective of Phase II in a clinical drug trial?

Accepted Answer

Therapeutic exploration and dose ranging

Answer

Human pharmacology and safety assessment

Answer

Therapeutic comparison with existing treatments

Answer

Post-marketing surveillance and monitoring

Question 9

Which category of drugs is difficult to market and highly expensive to produce?

Accepted Answer

Orphan drugs

Answer

Rare drugs

Answer

Over the counter drugs

Answer

Emergency drugs

Question 10

Therapeutic drug monitoring of plasma concentrations of antihypertensive drugs is not practiced because:

Accepted Answer

It is easier to measure the therapeutic effect of these drugs.

Answer

Determination of plasma level of these drugs is a tedious and long process.

Answer

The antihypertensive effect does not increase linearly with the dose.

Answer

All antihypertensive drugs are prodrugs.

General Pharmacology — MCQs

General Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?